Buying guide
Versius vs Ottava in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | CMR Surgical | Johnson & Johnson |
| Form factor | surgical | surgical |
| Maturity | commercial | pilot |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | Not announced |
| Capability claims | — | — |
| Brain | — | — |
| Verified deployments | 2CMR Surgical, CMR Surgical | 1United States |
| Privacy practices | — | — |
| Sources on file | 18 | 5 |
Editorial summaries
Versius
CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data. On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.
Ottava
J&J MedTech's Ottava is a soft-tissue general-surgery robotic platform with four arms integrated into the operating table, announced in 2020. It is pre-market: J&J submitted a De Novo request to the FDA in January 2026, and Ottava is not authorized to be marketed. DEPLOY classifies it research tier: J&J's corporate scale does not translate into verified surgical-robotics deployment, because the gating event (FDA clearance) has not occurred. By the framework, Ottava sits at the same research tier as far smaller pre-market entrants. There is no price; it is not sold.
Machine-readable: this page as markdown.